Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106544 | 0.77 | HDAC6 (0.36) | HDAC6NFKB1NFKB2RELAHDAC1 | |
| SCHEMBL15488438 | 0.71 | HDAC6 (0.37) | HDAC6NFKB1NFKB2RELAHDAC1 | |
| SCHEMBL27331623 | 0.69 | MT-CO2 (0.35) | HDAC6MT-CO2NFKB1NFKB2RELA | |
| SCHEMBL4815974 | 0.69 | MT-CO2 (0.33) | HDAC6MT-CO2NFKB1NFKB2RELA | |
| SCHEMBL111602 | 0.68 | CA14 (0.40) | HDAC6NFKB1NFKB2RELAHDAC1 | |
| SCHEMBL4693101 | 0.68 | HDAC6 (0.39) | HDAC6NFKB1NFKB2RELAHDAC1 | |
| SCHEMBL4595993 | 0.68 | CTSD (0.32) | HDAC6MT-CO2NFKB1NFKB2RELA | |
| SCHEMBL20668140 | 0.67 | MT-CO2 (0.33) | MT-CO2NFKB1NFKB2RELA | |
| SCHEMBL23901170 | 0.67 | CA14 (0.36) | HDAC6MT-CO2NFKB1NFKB2RELA | |
| SCHEMBL2578067 | 0.67 | CA14 (0.33) | HDAC6MT-CO2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | HDAC6 2950/4885MT-CO2 1564/4885NFKB1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.